Press Release
11 May 2021

GE Healthcare Acquires Zionexa

The Paris Private Equity team advised the shareholders of Zionexa, an innovative French start-up focusing on in-vivo biomarkers for targeted therapies in oncology, on its acquisition by GE Healthcare.

Founded in 2018, Zionexa develops and commercializes molecular imaging solutions for targeted therapies in oncology to improve therapeutic management in the patient’s pathway and provide them a better quality of life.

GE Healthcare is the global leader in contrast products, used in over 100 million imaging procedures worldwide each year.

The Goodwin team was led Thomas Maitrejean and included Simon Servan-Schreiber on corporate aspects and Charles-Henri de Gouvion Saint Cyr on tax aspects.